- Home
- CGAU vs ACLX Comparison
CGAU vs ACLX Comparison
Compare CGAU & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGAU | ACLX |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CGAU | ACLX |
|---|---|---|
| Price | $19.41 | $114.31 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 15 |
| Target Price | $16.00 | ★ $115.85 |
| AVG Volume (30 Days) | 1.7M | ★ 3.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,286,000.00 |
| Revenue This Year | $16.86 | $329.40 |
| Revenue Next Year | $20.33 | $151.37 |
| P/E Ratio | $11.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.41 | $47.86 |
| 52 Week High | $21.17 | $114.38 |
Technical Indicators
Market Signals| Indicator | CGAU | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 54.87 | 83.74 |
| Support Level | $16.97 | $64.61 |
| Resistance Level | $20.15 | N/A |
| Average True Range (ATR) | 1.11 | 1.42 |
| MACD | -0.02 | 3.64 |
| Stochastic Oscillator | 53.17 | 99.30 |
Price Performance
Historical ComparisonAbout CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.